Investigating the association between CYP2J2 inhibitors and QT prolongation: a literature review

References

• Aliwarga T, Raccor BS, Lemaitre RN, Sotoodehnia N, Gharib SA, Xu L, Totah RA. 2017. Enzymatic and free radical formation of cis- and trans- epoxyeicosatrienoic acids in vitro and in vivo. Free Radic Biol Med. 112:131–140. doi: 10.1016/j.freeradbiomed.2017.07.015.
   PubMed Web of Science ®Google Scholar
• Archer SL, Gragasin FS, Wu X, Wang S, McMurtry S, Kim DH, Platonov M, Koshal A, Hashimoto K, Campbell WB, et al. 2003. Endothelium-derived hyperpolarizing factor in human internal mammary artery is 11,12-epoxyeicosatrienoic acid and causes relaxation by activating smooth muscle BK Ca channels. Circulation. 107(5):769–776. doi: 10.1161/01.CIR.0000047278.28407.C2.
   PubMed Web of Science ®Google Scholar
• Arnold WR, Baylon JL, Tajkhorshid E, Das A. 2016. Asymmetric binding and metabolism of polyunsaturated fatty acids (PUFAs) by CYP2J2 epoxygenase. Biochemistry. 55(50):6969–6980. doi: 10.1021/acs.biochem.6b01037.
   PubMed Web of Science ®Google Scholar
• Arnold WR, Baylon JL, Tajkhorshid E, Das A. 2017. Arachidonic acid metabolism by human cardiovascular CYP2J2 is modulated by doxorubicin. Biochemistry. 56(51):6700–6712. doi: 10.1021/acs.biochem.7b01025.
   PubMed Web of Science ®Google Scholar
• Arnold WR, Weigle AT, Das A. 2018. Cross-talk of cannabinoid and endocannabinoid metabolism is mediated via human cardiac CYP2J2. J Inorg Biochem. 184:88–99. doi: 10.1016/j.jinorgbio.2018.03.016.
   PubMed Web of Science ®Google Scholar
• Batchu SN, Law E, Brocks DR, Falck JR, Seubert JM. 2009. Epoxyeicosatrienoic acid prevents postischemic electrocardiogram abnormalities in an isolated heart model. J Mol Cell Cardiol. 46(1):67–74. doi: 10.1016/j.yjmcc.2008.09.711.
   PubMed Web of Science ®Google Scholar
• Carnevale LN, Arango AS, Arnold WR, Tajkhorshid E, Das A. 2018. Endocannabinoid virodhamine is an endogenous inhibitor of human cardiovascular CYP2J2 epoxygenase. Biochemistry. 57(46):6489–6499. doi: 10.1021/acs.biochem.8b00691.
   PubMed Web of Science ®Google Scholar
• Chang S-Y, Chen C, Yang Z, Rodrigues AD. 2009. Further assessment of 17α-ethinyl estradiol as an inhibitor of different human cytochrome P450 forms in vitro. Drug Metab Dispos. 37(8):1667–1675. doi: 10.1124/dmd.109.026997.
   PubMed Web of Science ®Google Scholar
• Chaudhary KR, Batchu SN, Seubert JM. 2009. Cytochrome P450 enzymes and the heart. IUBMB Life. 61(10):954–960. doi: 10.1002/iub.241.
   PubMed Web of Science ®Google Scholar
• Cheong EJY, Goh JJN, Hong Y, Venkatesan G, Liu Y, Chiu GNC, Kojodjojo P, Chan ECY. 2017. Application of static modeling ­­in the prediction of in vivo drug–drug interactions between rivaroxaban and antiarrhythmic agents based on in vitro inhibition studies. Drug Metab Dispos. 45(3):260–268. doi: 10.1124/dmd.116.073890.
   PubMed Web of Science ®Google Scholar
• Cheong EJY, Ng DZW, Chin SY, Wang Z, Chan ECY. 2022. Application of a physiologically based pharmacokinetic model of rivaroxaban to prospective simulations of drug–drug–disease interactions with protein kinase inhibitors in cancer‐associated venous thromboembolism. Br J Clin Pharmacol. 88(5):2267–2283. doi: 10.1111/bcp.15158.
   PubMed Web of Science ®Google Scholar
• Cheong EJY, Teo DWX, Chua DXY, Chan ECY. 2019. Systematic development and verification of a physiologically based pharmacokinetic model of rivaroxaban. Drug Metab Dispos. 47(11):1291–1306. doi: 10.1124/dmd.119.086918.
   PubMed Web of Science ®Google Scholar
• Cojocaru V, Winn PJ, Wade RC. 2007. The ins and outs of cytochrome P450s. Biochim Biophys Acta. 1770(3):390–401. doi: 10.1016/j.bbagen.2006.07.005.
   PubMed Web of Science ®Google Scholar
• Darpo B. 2001. Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes. Eur Heart J Suppl. 3: k 70–K80. doi: 10.1016/S1520-765X(01)90009-4.
   Web of Science ®Google Scholar
• Duan J, Tao J, Zhai M, Li C, Zhou N, Lv J, Wang L, Lin L, Bai R. 2018. Anticancer drugs-related QTc prolongation, torsade de pointes and sudden death: current evidence and future research perspectives. Oncotarget. 9(39):25738–25749. doi: 10.18632/oncotarget.25008.
   PubMedGoogle Scholar
• Evangelista EA, Cho CW, Aliwarga T, Totah RA. 2020. Expression and function of eicosanoid-producing cytochrome P450 enzymes in solid tumors. Front Pharmacol. 11:828. doi: 10.3389/fphar.2020.00828.
   PubMed Web of Science ®Google Scholar
• Evangelista EA, Kaspera R, Mokadam NA, Jones JP, Totah RA. 2013. Activity, inhibition, and induction of cytochrome P450 2J2 in adult human primary cardiomyocytes. Drug Metab Dispos. 41(12):2087–2094. doi: 10.1124/dmd.113.053389.
   PubMed Web of Science ®Google Scholar
• Fährrolfes R, Bietz S, Flachsenberg F, Meyder A, Nittinger E, Otto T, Volkamer A, Rarey M. 2017. ProteinsPlus: a web portal for structure analysis of macromolecules. Nucleic Acids Res. 45(W1):W337–W343. doi: 10.1093/nar/gkx333.
   PubMed Web of Science ®Google Scholar
• Flachsenberg F, Meyder A, Sommer K, Penner P, Rarey M. 2020. A consistent scheme for gradient-based optimization of protein – ligand poses. J Chem Inf Model. 60(12):6502–6522. doi: 10.1021/acs.jcim.0c01095.
   PubMed Web of Science ®Google Scholar
• Garrido A, Lepailleur A, Mignani SM, Dallemagne P, Rochais C. 2020. hERG toxicity assessment: useful guidelines for drug design. Eur J Med Chem. 195:112290. doi: 10.1016/j.ejmech.2020.112290.
   PubMed Web of Science ®Google Scholar
• Gay SC, Roberts AG, Halpert JR. 2010. Structural features of cytochromes P450 and ligands that affect drug metabolism as revealed by x-ray crystallography and NMR. Future Med Chem. 2(9):1451–1468. doi: 10.4155/fmc.10.229.
   PubMed Web of Science ®Google Scholar
• Gotoh O. 1992. Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J Biol Chem. 267(1):83–90. doi: 10.1016/S0021-9258(18)48462-1.
   PubMed Web of Science ®Google Scholar
• Haddad PM, Anderson IM. 2002. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs. 62(11):1649–1671. doi: 10.2165/00003495-200262110-00006.
   PubMed Web of Science ®Google Scholar
• Hanwell MD, Curtis DE, Lonie DC, Vandermeersch T, Zurek E, Hutchison GR. 2012. Avogadro: an advanced semantic chemical editor, visualization, and analysis platform. J Cheminform. 4(1):17. doi: 10.1186/1758-2946-4-17.
   PubMed Web of Science ®Google Scholar
• Haque AKMM, Leong KH, Lo YL, Awang K, Nagoor NH. 2017. In vitro inhibitory mechanisms and molecular docking of 1′-S-1′-acetoxychavicol acetate on human cytochrome P450 enzymes. Phytomedicine. 31:1–9. doi: 10.1016/j.phymed.2017.05.002.
   PubMed Web of Science ®Google Scholar
• Heist EK, Ruskin JN. 2010. Drug-induced arrhythmia. Circulation. 122(14):1426–1435. doi: 10.1161/CIRCULATIONAHA.109.894725.
   PubMed Web of Science ®Google Scholar
• Heo J-K, Nguyen P-H, Kim W, Phuc N, Liu K-H. 2017. Inhibitory Effect of Selaginellins from Selaginella tamariscina (Beauv.) Spring against cytochrome P450 and Uridine 5′-diphosphoglucuronosyltransferase isoforms on human liver microsomes. Molecules. 22(10):1590. doi: 10.3390/molecules22101590.
   PubMed Web of Science ®Google Scholar
• Hoopes SL, Garcia V, Edin ML, Schwartzman ML, Zeldin DC. 2015. Vascular actions of 20-HETE. Prostaglandins Other Lipid Mediat. 120:9–16. doi: 10.1016/j.prostaglandins.2015.03.002.
   PubMed Web of Science ®Google Scholar
• Huguet J, Gaudette F, Michaud V, Turgeon J. 2019. Development and validation of probe drug cocktails for the characterization of CYP450-mediated metabolism by human heart microsomes. Xenobiotica. 49(2):187–199. doi: 10.1080/00498254.2018.1438684.
   PubMed Web of Science ®Google Scholar
• Ikemura N, Yamaori S, Kobayashi C, Kamijo S, Murayama N, Yamazaki H, Ohmori S. 2019. Inhibitory effects of antihypertensive drugs on human cytochrome P450 2J2 activity: potent inhibition by azelnidipine and manidipine. Chem Biol Interact. 306:1–9. doi: 10.1016/j.cbi.2019.04.005.
   PubMed Web of Science ®Google Scholar
• Jarrar YB, Cho S-A, Oh K-S, Kim D-H, Shin J-G, Lee S-J. 2013. Identification of cytochrome P450s involved in the metabolism of arachidonic acid in human platelets. Prostaglandins Leukot Essent Fatty Acids. 89(4):227–234. doi: 10.1016/j.plefa.2013.06.008.
   PubMed Web of Science ®Google Scholar
• Chohan PS, Mittal R, Javed A. 2015. Antipsychotic medication and QT prolongation. Pak J Med Sci. 31(5):1269–1271. doi: 10.12669/pjms.315.8998.
   PubMed Web of Science ®Google Scholar
• Jeon YJ, Kim JS, Hwang GH, Wu Z, Han HJ, Park SH, Chang W, Kim LK, Lee Y-M, Liu K-H, et al. 2015. Inhibition of cytochrome P450 2J2 by tanshinone IIA induces apoptotic cell death in hepatocellular carcinoma HepG2 cells. Eur J Pharmacol. 764:480–488. doi: 10.1016/j.ejphar.2015.07.047.
   PubMed Web of Science ®Google Scholar
• Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, Tunyasuvunakool K, Bates R, Žídek A, Potapenko A, et al. 2021. Highly accurate protein structure prediction with AlphaFold. Nature. 596(7873):583–589.,. doi: 10.1038/s41586-021-03819-2.
   PubMed Web of Science ®Google Scholar
• Kahma H, Aurinsalo L, Neuvonen M, Katajamäki J, Paludetto M-N, Viinamäki J, Launiainen T, Filppula AM, Tornio A, Niemi M, et al. 2021. An automated cocktail method for in vitro assessment of direct and time-dependent inhibition of nine major cytochrome P450 enzymes – application to establishing CYP2C8 inhibitor selectivity. Eur J Pharm Sci. 162:105810. doi: 10.1016/j.ejps.2021.105810.
   PubMed Web of Science ®Google Scholar
• Kamiya K, Niwa R, Mitcheson JS, Sanguinetti MC. 2006. Molecular determinants of hERG channel block. Mol Pharmacol. 69(5):1709–1716. doi: 10.1124/mol.105.020990.
   PubMed Web of Science ®Google Scholar
• Kannankeril P, Roden DM, Darbar D. 2010. Drug-induced long QT syndrome. Pharmacol Rev. 62(4):760–781. doi: 10.1124/pr.110.003723.
   PubMed Web of Science ®Google Scholar
• Karkhanis A, Lam HY, Venkatesan G, Koh SK, Chai CLL, Zhou L, Hong Y, Kojodjojo P, Chan ECY. 2016. Multiple modes of inhibition of human cytochrome P450 2J2 by dronedarone, amiodarone and their active metabolites. Biochem Pharmacol. 107:67–80. doi: 10.1016/j.bcp.2016.03.005.
   PubMed Web of Science ®Google Scholar
• Karkhanis A, Tram NDT, Chan ECY. 2017. Effects of dronedarone, amiodarone and their active metabolites on sequential ­metabolism of arachidonic acid to epoxyeicosatrienoic and dihydroxyeicosatrienoic acids. Biochem Pharmacol. 146:188–198. doi: 10.1016/j.bcp.2017.09.012.
   PubMed Web of Science ®Google Scholar
• Karkhanis AV, Venkatesan G, Kambayashi R, Hui Leow JW, Han MQ, Izumi-Nakaseko H, Goto A, Sheng Pang JK, Soh BS, Kojodjojo P, et al. 2022. Site-directed deuteration of dronedarone preserves cytochrome P4502J2 activity and mitigates its cardiac adverse effects in canine arrhythmic hearts. Acta Pharm Sin B. 12(10):3905–3923. doi: 10.1016/j.apsb.2022.03.008.
   PubMed Web of Science ®Google Scholar
• Kaspera R, Kirby BJ, Sahele T, Collier AC, Kharasch ED, Unadkat JD, Totah RA. 2014. Investigating the contribution of CYP2J2 to ritonavir metabolism in vitro and in vivo. Biochem Pharmacol. 91(1):109–118. doi: 10.1016/j.bcp.2014.06.020.
   PubMed Web of Science ®Google Scholar
• Kim PY, Irizarry-Caro JA, Ramesh T, Iliescu C, Lopez-Mattei JC. 2021. How to diagnose and manage QT prolongation in cancer patients. JACC CardioOncol. 3(1):145–149. doi: 10.1016/j.jaccao.2021.01.002.
   PubMedGoogle Scholar
• Kojima A, Nadai M, Murayama N, Yamazaki H, Katoh M. 2022. Effects of multi-kinase inhibitors on the activity of cytochrome P450 2J2. Xenobiotica. 52(7):669–675. doi: 10.1080/00498254.2022.2137068.
   PubMed Web of Science ®Google Scholar
• Kroetz DL, Zeldin DC. 2002. Cytochrome P450 pathways of arachidonic acid metabolism. Curr Opin Lipidol. 13(3):273–283. doi: 10.1097/00041433-200206000-00007.
   PubMed Web of Science ®Google Scholar
• Lafite P, André F, Graves J, Zeldin D, Dansette P, Mansuy D. 2018. Role of Arginine 117 in substrate recognition by human cytochrome P450 2J2. Int J Mol Sci. 19(7):2066. doi: 10.3390/ijms19072066.
   PubMed Web of Science ®Google Scholar
• Lafite P, Dijols S, Zeldin DC, Dansette PM, Mansuy D. 2007. Selective, competitive and mechanism-based inhibitors of human cytochrome P450 2J2. Arch Biochem Biophys. 464(2):155–168. doi: 10.1016/j.abb.2007.03.028.
   PubMed Web of Science ®Google Scholar
• Lee B, Wu Z, Sung SH, Lee T, Song K-S, Lee MY, Liu K-H. 2014. Potential of decursin to inhibit the human cytochrome P450 2J2 isoform. Food Chem Toxicol. 70:94–99. doi: 10.1016/j.fct.2014.04.020.
   PubMed Web of Science ®Google Scholar
• Lee CA, Jones JP, Katayama J, Kaspera R, Jiang Y, Freiwald S, Smith E, Walker GS, Totah RA. 2012. Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity. Drug Metab Dispos. 40(5):943–951. doi: 10.1124/dmd.111.043505.
   PubMed Web of Science ®Google Scholar
• Lee CA, Neul D, Clouser-Roche A, Dalvie D, Wester MR, Jiang Y, Jones JP, Freiwald S, Zientek M, Totah RA. 2010. Identification of novel substrates for human cytochrome P450 2J2. Drug Metab Dispos. 38(2):347–356. doi: 10.1124/dmd.109.030270.
   PubMed Web of Science ®Google Scholar
• Lee CM, Lee J, Jang S-N, Shon JC, Wu Z, Park K, Liu K-H, Park S-H. 2020. 6,8-diprenylorobol Induces apoptosis in human hepatocellular carcinoma cells via activation of FOXO3 and Inhibition of CYP2J2. Oxid Med Cell Longev. 2020:8887251. doi: 10.1155/2020/8887251.
   PubMed Web of Science ®Google Scholar
• Lee E, Kim J-H, Shon JC, Wu Z, Kim HJ, Gim M, Lee T, Liu K-H. 2018. Terfenadone is a strong inhibitor of CYP2J2 present in the human liver and intestinal microsomes. Drug Metab Pharmacokinet. 33(3):159–163. doi: 10.1016/j.dmpk.2018.02.001.
   PubMed Web of Science ®Google Scholar
• Lee E, Wu Z, Shon JC, Liu K-H. 2015. Danazol inhibits cytochrome P450 2J2 activity in a substrate-independent manner. Drug Metab Dispos. 43(8):1250–1253. doi: 10.1124/dmd.115.064345.
   PubMed Web of Science ®Google Scholar
• Lee H, Lu T, Weintraub NL, VanRollins M, Spector AA, Shibata EF. 1999. Effects of epoxyeicosatrienoic acids on the cardiac sodium channels in isolated rat ventricular myocytes. J Physiol. 519 Pt 1(Pt 1):153–168. doi: 10.1111/j.1469-7793.1999.0153o.x.
   PubMed Web of Science ®Google Scholar
• Lei M, Wu L, Terrar DA, Huang CL-H. 2018. Modernized classification of cardiac antiarrhythmic drugs. Circulation. 138(17):1879–1896. doi: 10.1161/CIRCULATIONAHA.118.035455.
   PubMed Web of Science ®Google Scholar
• Leow JWH, Gu Y, Chan ECY. 2023. Investigating the relevance of CYP2J2 inhibition for drugs known to cause intermediate to high risk torsades de pointes. Eur J Pharm Sci. 187:106475. doi: 10.1016/j.ejps.2023.106475.
   PubMed Web of Science ®Google Scholar
• Leow JWH, Verma RK, Lim ABH, Fan H, Chan ECY. 2021. Atypical kinetics of cytochrome P450 2J2: epoxidation of arachidonic acid and reversible inhibition by xenobiotic inhibitors. Eur J Pharm Sci. 164:105889. doi: 10.1016/j.ejps.2021.105889.
   PubMed Web of Science ®Google Scholar
• Li M, Ramos LG. 2017. Drug-Induced QT Prolongation And Torsades de Pointes.
   Google Scholar
• Lim SYM, Alshagga MA, Alshawsh MA, Ong CE, Pan Y. 2022. In vitro effects of 95% khat ethanol extract (KEE) on human recombinant cytochrome P450 (CYP)1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C19, CYP2E1, CYP2J2 and CYP3A5. Drug Metab Pers Ther. 37(1):55–67. doi: 10.1515/dmpt-2021-1000196.
   Google Scholar
• Lin H, Zhang H, Hollenberg PF. 2018. Formation of both heme and apoprotein adducts contributes to the mechanism-based inactivation of human CYP2J2 by 17 α -ethynylestradiol. Drug Metab Dispos. 46(6):813–822. doi: 10.1124/dmd.118.080903.
   PubMed Web of Science ®Google Scholar
• Lin H-L, Zhang H, Walker VJ, D’Agostino J, Hollenberg PF. 2017. Heme modification contributes to the mechanism-based inactivation of human cytochrome P450 2J2 by two terminal acetylenic compounds. Drug Metab Dispos. 45(9):990–999. doi: 10.1124/dmd.117.075846.
   PubMed Web of Science ®Google Scholar
• Lu J, Liu D, Zhou X, Chen A, Jiang Z, Ye X, Liu M, Wang X. 2018. Plant natural product plumbagin presents potent inhibitory effect on human cytochrome P450 2J2 enzyme. Phytomedicine. 39:137–145. doi: 10.1016/j.phymed.2017.12.026.
   PubMed Web of Science ®Google Scholar
• Lu T, Hoshi T, Weintraub NL, Spector AA, Lee H-C. 2001. Activation of ATP-sensitive K + channels by epoxyeicosatrienoic acids in rat cardiac ventricular myocytes. J Physiol. 537(Pt 3):811–827. doi: 10.1111/j.1469-7793.2001.00811.x.
   PubMed Web of Science ®Google Scholar
• Mamoshina P, Rodriguez B, Bueno-Orovio A. 2021. Toward a broader view of mechanisms of drug cardiotoxicity. Cell Rep Med. 2(3):100216. doi: 10.1016/j.xcrm.2021.100216.
   PubMedGoogle Scholar
• Matsumoto S, Hirama T, Kim HJ, Nagata K, Yamazoe Y. 2003. In vitro inhibition of human small intestinal and liver microsomal astemizole O -demethylation: different contribution of CYP2J2 in the small intestine and liver. Xenobiotica. 33(6):615–623. doi: 10.1080/0049825031000105778.
   PubMed Web of Science ®Google Scholar
• Matsumoto S, Hirama T, Matsubara T, Nagata K, Yamazoe Y. 2002. Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole. Drug Metab Dispos. 30(11):1240–1245. doi: 10.1124/dmd.30.11.1240.
   PubMed Web of Science ®Google Scholar
• McDougle DR, Baylon JL, Meling DD, Kambalyal A, Grinkova YV, Hammernik J, Tajkhorshid E, Das A. 2015. Incorporation of charged residues in the CYP2J2 F-G loop disrupts CYP2J2–lipid bilayer interactions. Biochim Biophys Acta. 1848(10 Pt A):2460–2470. doi: 10.1016/j.bbamem.2015.07.015.
   PubMed Web of Science ®Google Scholar
• Midlik A, Navrátilová V, Moturu TR, Koča J, Svobodová R, Berka K. 2021. Uncovering of cytochrome P450 anatomy by SecStrAnnotator. Sci Rep. 11(1):12345. doi: 10.1038/s41598-021-91494-8.
   PubMed Web of Science ®Google Scholar
• Mitcheson JS. 2008. hERG potassium channels and the structural basis of drug-induced arrhythmias. Chem Res Toxicol. 21(5):1005–1010. doi: 10.1021/tx800035b.
   PubMed Web of Science ®Google Scholar
• Obach RS. 2022. Linezolid metabolism is catalyzed by cytochrome P450 2J2, 4F2, and 1B1. Drug Metab Dispos. 50(4):413–421. doi: 10.1124/dmd.121.000776.
   PubMed Web of Science ®Google Scholar
• Onakpoya IJ, Heneghan CJ, Aronson JK. 2016. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC Med. 14(1):10. doi: 10.1186/s12916-016-0553-2.
   PubMed Web of Science ®Google Scholar
• Paludetto M-N, Kurkela M, Kahma H, Backman JT, Niemi M, Filppula AM. 2023. Hydroxychloroquine is metabolized by cytochrome P450 2D6, 3A4, and 2C8, and inhibits cytochrome P450 2D6, while its metabolites also inhibit cytochrome P450 3A in vitro. Drug Metab Dispos. 51(3):293–305. doi: 10.1124/dmd.122.001018.
   PubMed Web of Science ®Google Scholar
• Park S-H, Lee J, Shon JC, Phuc NM, Jee JG, Liu K-H. 2018. The inhibitory potential of Broussochalcone A for the human cytochrome P450 2J2 isoform and its anti-cancer effects via FOXO3 activation. Phytomedicine. 42:199–206. doi: 10.1016/j.phymed.2018.03.032.
   PubMed Web of Science ®Google Scholar
• Park S-H, Phuc NM, Lee J, Wu Z, Kim J, Kim H, Kim ND, Lee T, Song K-S, Liu K-H. 2017. Identification of acetylshikonin as the novel CYP2J2 inhibitor with anti-cancer activity in HepG2 cells. Phytomedicine. 24:134–140. doi: 10.1016/j.phymed.2016.12.001.
   PubMed Web of Science ®Google Scholar
• Phuc NM, Wu Z, O Y, Lee J-H, Oh S, Song G-Y, Liu K-H. 2017. LKY-047: first selective inhibitor of cytochrome P450 2J2. Drug Metab Dispos. 45(7):765–769. doi: 10.1124/dmd.117.075036.
   PubMed Web of Science ®Google Scholar
• Poulos TL. 2014. Heme enzyme structure and function. Chem Rev. 114(7):3919–3962. doi: 10.1021/cr400415k.
   PubMed Web of Science ®Google Scholar
• Ren S, Zeng J, Mei Y, Zhang JZH, Yan SF, Fei J, Chen L. 2013. Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors. Drug Metab Dispos. 41(1):60–71. doi: 10.1124/dmd.112.048264.
   PubMed Web of Science ®Google Scholar
• Rocic P, Schwartzman ML. 2018. 20-HETE in the regulation of vascular and cardiac function. Pharmacol Ther. 192:74–87. doi: 10.1016/j.pharmthera.2018.07.004.
   PubMed Web of Science ®Google Scholar
• Sanguinetti MC, Curran ME, Keating MT. 1995. A Mechanistic Link between an Inherited and an Acquired Cardiac Arrhythmia: HERG Encodes the IKr Potassium Channel.
   Google Scholar
• Schellhammer I, Rarey M. 2007. TrixX: structure-based molecule indexing for large-scale virtual screening in sublinear time. J Comput Aided Mol Des. 21(5):223–238. doi: 10.1007/s10822-007-9103-5.
   PubMed Web of Science ®Google Scholar
• Schöning-Stierand K, Diedrich K, Ehrt C, Flachsenberg F, Graef J, Sieg J, Penner P, Poppinga M, Ungethüm A, Rarey M. 2022. Proteins Plus : a comprehensive collection of web-based molecular modeling tools. Nucleic Acids Res. 50(W1):W611–W615. doi: 10.1093/nar/gkac305.
   PubMed Web of Science ®Google Scholar
• Schöning-Stierand K, Diedrich K, Fährrolfes R, Flachsenberg F, Meyder A, Nittinger E, Steinegger R, Rarey M. 2020. ProteinsPlus: interactive analysis of protein–ligand binding interfaces. Nucleic Acids Res. 48(W1):W48–W53. doi: 10.1093/nar/gkaa235.
   PubMed Web of Science ®Google Scholar
• Senda A, Mukai Y, Hayakawa T, Kato Y, Eliasson E, Rane A, Toda T, Inotsume N. 2017. Angiotensin II receptor blockers inhibit the generation of epoxyeicosatrienoic acid from arachidonic acid in recombinant CYP2C9, CYP2J2 and human liver microsomes. Basic Clin Pharmacol Toxicol. 121(4):239–245. doi: 10.1111/bcpt.12789.
   PubMed Web of Science ®Google Scholar
• Shon JC, Phuc NM, Kim WC, Heo JK, Wu Z, Lee H, Liu K-H. 2017. Acetylshikonin is a novel non-selective cytochrome P450 inhibitor. Biopharm Drug Dispos. 38(9):553–556. doi: 10.1002/bdd.2101.
   PubMed Web of Science ®Google Scholar
• Siramshetty VB, Nickel J, Omieczynski C, Gohlke B-O, Drwal MN, Preissner R. 2016. WITHDRAWN—a resource for withdrawn and discontinued drugs. Nucleic Acids Res. 44(D1):D1080–D1086. doi: 10.1093/nar/gkv1192.
   PubMed Web of Science ®Google Scholar
• Stierand K, Rarey M. 2010. Drawing the PDB: protein − ligand complexes in two dimensions. ACS Med Chem Lett. 1(9):540–545. doi: 10.1021/ml100164p.
   PubMed Web of Science ®Google Scholar
• Sun H, Huang R, Xia M, Shahane S, Southall N, Wang Y. 2017. Prediction of hERG Liability - using SVM classification, bootstrapping and jackknifing. Mol Inform. 36(4):1600126. doi: 10.1002/minf.201600126.
   Web of Science ®Google Scholar
• Surawicz B. 1989. Electrophysiologic substrate of torsade de pointes: dispersion of repolarization or early afterdepolarizations? J Am Coll Cardiol. 14(1):172–184. doi: 10.1016/0735-1097(89)90069-7.
   PubMed Web of Science ®Google Scholar
• Tallima H, El Ridi R. 2018. Arachidonic acid: physiological roles and potential health benefits – a review. J Adv Res. 11:33–41. doi: 10.1016/j.jare.2017.11.004.
   PubMed Web of Science ®Google Scholar
• Tang LWT, Wu G, Chan ECY. 2022. Identification of Infigratinib as a potent reversible inhibitor and mechanism-based inactivator of CYP2J2: nascent evidence for a potential in vivo metabolic drug-drug interaction with rivaroxaban. J Pharmacol Exp Ther. 382(2):123–134. doi: 10.1124/jpet.122.001222.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. 2005. The Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals [Internet]. [accessed 2023 Sep 8]. doi: 10.1163/ej.9789004163300.i-1081.897.
   Google Scholar
• Van Noord C, Eijgelsheim M, Stricker B. 2010. Drug- and non-drug-associated QT interval prolongation: QT interval prolongation. Br J Clin Pharmacol. 70(1):16–23. doi: 10.1111/j.1365-2125.2010.03660.x.
   PubMed Web of Science ®Google Scholar
• Vandenberg JI, Perry MD, Perrin MJ, Mann SA, Ke Y, Hill AP. 2012. hERG K + Channels: structure, function, and clinical significance. Physiol Rev. 92(3):1393–1478. doi: 10.1152/physrev.00036.2011.
   PubMed Web of Science ®Google Scholar
• Varadi M, Anyango S, Deshpande M, Nair S, Natassia C, Yordanova G, Yuan D, Stroe O, Wood G, Laydon A, et al. 2022. AlphaFold Protein Structure Database: massively expanding the structural coverage of protein-sequence space with high-accuracy models. Nucleic Acids Res. 50(D1):D439–D444.,. doi: 10.1093/nar/gkab1061.
   PubMed Web of Science ®Google Scholar
• Volkamer A, Kuhn D, Grombacher T, Rippmann F, Rarey M. 2012. Combining Global and Local Measures for Structure-Based Druggability Predictions. J Chem Inf Model. 52(2):360–372. doi: 10.1021/ci200454v.
   PubMed Web of Science ®Google Scholar
• Walker VJ, Griffin AP, Hammar DK, Hollenberg PF. 2016. Metabolism of anandamide by human cytochrome P450 2J2 in the reconstituted system and human intestinal microsomes. J Pharmacol Exp Ther. 357(3):537–544. doi: 10.1124/jpet.116.232553.
   PubMed Web of Science ®Google Scholar
• Wang W, MacKinnon R. 2017. Cryo-em structure of the open human ether-à-go-go -related K + channel hERG. Cell. 169(3):422–430.e10. doi: 10.1016/j.cell.2017.03.048.
   PubMed Web of Science ®Google Scholar
• Wang Z, Yong Chan EC. 2022. Inhibition of cytochrome P450 2J2-MEDIATED METABOLISM of rivaroxaban and arachidonic acid by ibrutinib and osimertinib. Drug Metab Dispos. 50(10):1332–1341. doi: 10.1124/dmd.122.000928.
   PubMed Web of Science ®Google Scholar
• Westphal C, Spallek B, Konkel A, Marko L, Qadri F, DeGraff LM, Schubert C, Bradbury JA, Regitz-Zagrosek V, Falck JR, et al. 2013. CYP2J2 Overexpression Protects against Arrhythmia Susceptibility in Cardiac Hypertrophy. Da Costa Martins PA, editor. PLoS One. 8(8):e73490. doi: 10.1371/journal.pone.0073490.
   PubMed Web of Science ®Google Scholar
• Wu J, Wu J, Zipes DP. 2002. Early after depolarizations, U waves, and Torsades de Pointes. Circulation. 105(6):675–676. doi: 10.1161/circ.105.6.675.
   PubMed Web of Science ®Google Scholar
• Wu S, Moomaw CR, Tomer KB, Falck JR, Zeldin DC. 1996. Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem. 271(7):3460–3468. doi: 10.1074/jbc.271.7.3460.
   PubMed Web of Science ®Google Scholar
• Wu Z, Lee D, Joo J, Shin J-H, Kang W, Oh S, Lee DY, Lee S-J, Yea SS, Lee HS, et al. 2013. CYP2J2 and CYP2C19 are the major enzymes responsible for metabolism of albendazole and fenbendazole in human liver microsomes and recombinant P450 assay systems. Antimicrob Agents Chemother. 57(11):5448–5456. doi: 10.1128/AAC.00843-13.
   PubMed Web of Science ®Google Scholar
• Xiao Y-F, Huang L, Morgan JP. 1998. Cytochrome P450: a novel system modulating Ca 2+ channels and contraction in mammalian heart cells. J Physiol. 508 (Pt 3)(Pt 3):777–792. doi: 10.1111/j.1469-7793.1998.777bp.x.
   PubMed Web of Science ®Google Scholar
• Xu L, Chen LY. 2020. Molecular determinant of substrate binding and specificity of cytochrome P450 2J2. Sci Rep. 10(1):22267. doi: 10.1038/s41598-020-79284-0.
   PubMed Web of Science ®Google Scholar
• Xu M, Jiang L, Wu T, Chu J, Wei Y, Aa J, Wang G, Hao H, Ju W, Li P. 2018. Inhibitory Effects of Danshen components on CYP2C8 and CYP2J2. Chem Biol Interact. 289:15–22. doi: 10.1016/j.cbi.2018.04.011.
   PubMed Web of Science ®Google Scholar
• Yano JK, Wester MR, Schoch GA, Griffin KJ, Stout CD, Johnson EF. 2004. The Structure of Human microsomal cytochrome P450 3A4 determined by X-ray Crystallography to 2.05-Å resolution. J Biol Chem. 279(37):38091–38094. doi: 10.1074/jbc.C400293200.
   PubMed Web of Science ®Google Scholar
• Yoo HH, Kim NS, Lee J, Sohn DR, Jin C, Kim DH. 2009. Characterization of human cytochrome P450 enzymes involved in the biotransformation of eperisone. Xenobiotica. 39(1):1–10. doi: 10.1080/00498250802509448.
   PubMed Web of Science ®Google Scholar
• Zeldin DC. 2001. Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem. 276(39):36059–36062. doi: 10.1074/jbc.R100030200.
   PubMed Web of Science ®Google Scholar
• Zhao T, Li X, Chen Y, Du J, Chen X, Wang D, Wang L, Zhao S, Wang C, Meng Q, et al. 2022. Risk assessment and molecular mechanism study of drug-drug interactions between rivaroxaban and tyrosine kinase inhibitors mediated by CYP2J2/3A4 and BCRP/P-gp. Front Pharmacol. 13:914842. doi: 10.3389/fphar.2022.914842.
   PubMed Web of Science ®Google Scholar
• Zordoky BNM, El-Kadi AOS. 2010. Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases. Pharmacol Ther. 125(3):446–463. doi: 10.1016/j.pharmthera.2009.12.002.
   PubMed Web of Science ®Google Scholar